Ann: Cancer pilot study success, page-48

For me, this is the crux of the announcement…..

“The ability of Phylogica’s delivery system to kill cancers from the inside and improve the efficacy of existing drugs is a potential paradigm shift for cancer therapeutics because it opens up the intracellular target landscape to next generation biologics drugs such as proteins.”

This is not just about intracellular delivery of OmoMyc; this is not just about treating breast cancer. There are much, much broader implications here imo.

The phylomer peptide fusion was demonstrated to significantly boost the efficacy of two established cancer therapies - Cetuximab and Docetaxel. Between them, these two drugs are used in the treatment of breast, non small cell lung, head and neck, metastatic prostate, advanced stomach, metastatic colorectal cancer and squamous cell carcinoma of the skin and are also being trialed in ovarian, bladder, small cell lung, and pancreatic cancers, soft tissue sarcoma and melanoma.

Hence the “potential paradigm shift for cancer therapeutics” comment.

Fantastic news.